Roche's Divarasib Outperforms Existing Treatments for Advanced Lung Cancer in Phase III Study

Roche announced positive Phase III trial results for its experimental KRAS G12C inhibitor, divarasib, in patients with previously treated advanced non-small cell lung cancer. The drug demonstrated superior progression-free and overall survival compared to current approved therapies, with no new safety concerns. Roche plans to seek regulatory approval based on these findings.